Clinical, Pathological and Molecular Insights on KRAS, NRAS, BRAF, PIK3CA and TP53 Mutations in Metastatic Colorectal Cancer Patients from Northeastern Romania

被引:3
|
作者
Afrasanie, Vlad-Adrian [1 ,2 ]
Marinca, Mihai-Vasile [1 ,2 ]
Gafton, Bogdan [1 ,2 ]
Alexa-Stratulat, Teodora [1 ,2 ]
Rusu, Alexandra [1 ]
Froicu, Eliza-Maria [1 ,2 ]
Sur, Daniel [3 ,4 ]
Lungulescu, Cristian Virgil [5 ]
Popovici, Larisa [1 ]
Lefter, Andrei-Vlad [1 ]
Afrasanie, Irina [6 ]
Ivanov, Anca-Viorica [7 ]
Miron, Lucian [1 ,2 ]
Rusu, Cristina [8 ]
机构
[1] Reg Inst Oncol, Dept Med Oncol, Iasi 700483, Romania
[2] Grigore T Popa Univ Med & Pharm, Fac Med, Dept Oncol, Iasi 700115, Romania
[3] Oncol Inst Prof Dr Ion Chiricuta, Dept Med Oncol, Cluj Napoca 400015, Romania
[4] Iuliu Hatieganu Univ Med & Pharm, Dept Med Oncol 11, Cluj Napoca 400347, Romania
[5] Univ Med & Pharm Craiova, Dept Oncol, Craiova 200349, Romania
[6] Emergency Clin Hosp Sf Spiridon, Dept Cardiol, Iasi 700111, Romania
[7] Grigore T Popa Univ Med & Pharm, Fac Med, Dept Pediat, Iasi 700115, Romania
[8] Grigore T Popa Univ Med & Pharm, Fac Med, Dept Genet, Iasi 700115, Romania
关键词
metastatic colorectal cancer; RAS; BRAF; PIK3CA; TP53; MICROSATELLITE INSTABILITY; POOLED ANALYSIS; RAS MUTATIONS; PROGNOSIS; IMPACT;
D O I
10.3390/ijms241612679
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutations in RAS, BRAF, PIK3CA, and TP53 are well-established genetic abnormalities in metastatic colorectal cancer (mCRC). However, limited information is available for patients from Eastern Europe, including Romania. In this retrospective analysis, we investigated 104 mCRC patients from the Northeastern region of Romania to determine the frequency, distribution, coexistence, and clinicopathological and molecular correlations of these mutations. TP53 was the most frequently mutated gene (73.1%), followed by KRAS (45.2%) and PIK3CA (6.7%). Patients with KRAS mutant tumors and wild-type TP53 genotype were found to have no personal history of gastrointestinal cancer (p = 0.02, p = 0.007). KRAS mutations in exon 3 were associated with the female gender (p = 0.02) and the absence of lymph node invasion (p = 0.02). PIK3CA mutations were linked to the absence of lymph node invasion (p = 0.006). TP53 mutations were associated with KRAS mutations in exon 2 (p = 0.006), ulcerated histopathologic type (p = 0.04), and G2 differentiation (p = 0.01). It provides novel insights into genetic variations specific to the population from Northeastern Romania, which has been underrepresented in previous studies within Eastern Europe. Furthermore, our findings enable the development of genetic profiles in a developing country with limited access to specialized genetic tests and facilitate comparisons with other populations.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases
    Jing Zhang
    Jianming Zheng
    Yinghong Yang
    Junliang Lu
    Jie Gao
    Tao Lu
    Jian Sun
    Hui Jiang
    Yan Zhu
    Yuhui Zheng
    Zhiyong Liang
    Tonghua Liu
    [J]. Scientific Reports, 5
  • [22] Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases
    Zhang, Jing
    Zheng, Jianming
    Yang, Yinghong
    Lu, Junliang
    Gao, Jie
    Lu, Tao
    Sun, Jian
    Jiang, Hui
    Zhu, Yan
    Zheng, Yuhui
    Liang, Zhiyong
    Liu, Tonghua
    [J]. SCIENTIFIC REPORTS, 2015, 5
  • [23] Frequency and coexistence of KRAS, NRAS, BRAF and PIK3CA mutations and occurrence of MMR deficiency in Danish colorectal cancer patients
    Poulsen, Tim Svenstrup
    de Oliveira, Douglas Vinicius Nogueira Perez
    Espersen, Maiken Lise Marcker
    Klarskov, Louise Laurberg
    Skovrider-Ruminski, Wojciech
    Hogdall, Estrid
    [J]. APMIS, 2021, 129 (02) : 61 - 69
  • [24] Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond
    Katsios, Christos
    Ziogas, Dimosthenis E.
    Roukos, Dimitrios H.
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 4 (05) : 525 - 529
  • [25] KRAS, NRAS, BRAF, PIK3CA, and AKT1 signatures in colorectal cancer patients in south-eastern Romania
    Brinzan, Costel Stelian
    Aschie, Mariana
    Cozaru, Georgeta Camelia
    Deacu, Mariana
    Dumitru, Eugen
    Burlacu, Ionut
    Mitroi, Anca
    [J]. MEDICINE, 2022, 101 (40) : E30979
  • [26] KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
    De Roock, Wendy
    De Vriendt, Veerle
    Normanno, Nicola
    Ciardiello, Fortunato
    Tejpar, Sabine
    [J]. LANCET ONCOLOGY, 2011, 12 (06): : 594 - 603
  • [27] KRAS, BRAF, PIK3CA MUTATIONS AND PTEN EXPRESSION IN HUMAN COLORECTAL CANCER - RELATIONSHIP WITH METASTATIC COLORECTAL CANCER
    Wang, X.
    Li, H.
    Lu, Y.
    Zhao, Q.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 64 - 64
  • [28] CLINICOPATHOLOGICAL FEATURES OF KRAS, NRAS, BRAF AND PIK3CA MUTATIONS IN JAPANESE PATIENTS WITH MCRC
    Kawazoe, Akihito
    Shitara, Kohei
    Bando, Hideaki
    Kuboki, Yasutoshi
    Kadota, Tomohiro
    Okamoto, Wataru
    Kojima, Takashi
    Fuse, Nozomu
    Yoshino, Takayuki
    [J]. ANNALS OF ONCOLOGY, 2014, 25
  • [29] Biochip detection of KRAS, BRAF, and PIK3CA somatic mutations in colorectal cancer patients
    M. A. Emelyanova
    F. A. Amossenko
    A. V. Semyanikhina
    V. A. Aliev
    Yu. A. Barsukov
    L. N. Lyubchenko
    T. V. Nasedkina
    [J]. Molecular Biology, 2015, 49 : 550 - 559
  • [30] Biochip detection of KRAS, BRAF, and PIK3CA somatic mutations in colorectal cancer patients
    Emelyanova, M. A.
    Amossenko, F. A.
    Semyanikhina, A. V.
    Aliev, V. A.
    Barsukov, Yu. A.
    Lyubchenko, L. N.
    Nasedkina, T. V.
    [J]. MOLECULAR BIOLOGY, 2015, 49 (04) : 550 - 559